EYPT

EYPT

USD

EyePoint Pharmaceuticals Inc. Common Stock

$12.390+0.260 (2.143%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$12.130

Kõrge

$12.950

Madal

$11.960

Maht

4.59M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.0B

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

1.08M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $3.91Praegune $12.390Kõrge $14.91

Seotud uudised

GlobeNewswire

EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with

Vaata rohkem
EyePoint Announces Pricing of Public Offering
GlobeNewswire

EyePoint Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with

Vaata rohkem
EyePoint Announces Proposed Public Offering of Common Stock
GlobeNewswire

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data

Vaata rohkem
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema